<DOC>
	<DOCNO>NCT01548677</DOCNO>
	<brief_summary>This randomized phase II trial patient HER2 negative primary Breast Cancer ( BC ) completing ( neo ) adjuvant chemotherapy surgery detectable circulate tumour cell ( CTC ) peripheral blood . Eligible patient randomise 1:1 ratio either trastuzumab arm observation arm .</brief_summary>
	<brief_title>Efficacy Study Herceptin Treat HER2-negative CTC Breast Cancer</brief_title>
	<detailed_description>This randomized phase II trial patient HER2 negative primary BC completing ( neo ) adjuvant chemotherapy surgery detectable CTC ( ) peripheral blood ( see eligibility criterion detail ) . Eligible patient randomize 1:1 ratio either trastuzumab arm observation arm . Patients randomize trastuzumab arm receive total 6 intravenous ( IV ) administration every 3 week ( load dose 8 mg/kg IV 5 cycle 6 mg/kg every 3 week ) . Patients randomized observation arm shall observe 18 week . Left ventricular ejection fraction ( LVEF ) assessment ( MUGA and/or ECHO ) do baseline patient randomize . The next LVEF assessment week 9 week 18 do patient randomize trastuzumab arm . Patient register CTC negative result followed-up .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Neoplastic Cells , Circulating</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Age ≥ 18 year Written inform consent must give accord ICH/GCP , national/local regulation Availability peripheral blood draw CTC blood test Tumor block minimum 10 unstained slide 4 μm primary tumor must available prior registration centralize HER2 test ER status available Adequately excise nonmetastatic nonrelapsed operable primary invasive HER2negative adenocarcinoma breast * : patient complete either adjuvant chemotherapy neoadjuvant chemotherapy ; case residual invasive disease breast lymph node require ( complete pathological response ) adjuvant chemotherapy treatment plan . Prior chemotherapy doxorubicin restrict total dose 360 mg/m2 epirubicin restrict total dose 720 mg/m2 allow No prior use antiHER2 therapy reason immunotherapy BC No concomitant use bisphosphonate therapy denosumab reason . Prior use agent allow provide last treatment receive least 4 week registration study No prior mediastinal irradiation except internal mammary node irradiation present BC Concomitant adjuvant hormonal therapy radiotherapy ( applicable ) allow upon physician 's choice The interval definitive surgery ( neoadjuvant population ) end adjuvant chemotherapy ( adjuvant population ) registration must least 3 week 24 week No evidence unresolved unstable toxicity prior surgery , adjuvant chemotherapy radiotherapy No history prior invasive breast carcinoma , except BC diagnose treated entry . Unifocal multifocal unilateral ( one breast ) unifocal multifocal synchronous bilateral breast ( breast ) cancer acceptable invasive tumor focus HER2 negative . History previous ductal carcinoma situ allow No history malignant neoplasms past 5 year except curatively treat basal squamous cell carcinoma skin No prior autologous allogeneic stem cell transplantation No history serious cardiac illness medical condition , include confine : History document congestive heart failure High risk uncontrolled arrhythmias Angina pectoris require antianginal medication Clinically significant valvular heart disease Evidence transmural infarction ECG Poorly control hypertension ( e.g . systolic &gt; 180 mm Hg diastolic &gt; 100 mm Hg ) No history concurrent serious disease may interfere plan treatment , include severe pulmonary condition Absence psychological , familial , sociological geographical condition potentially hamper compliance study protocol followup schedule ; condition discuss patient registration WHO performance status 01 No concurrent participation another trial No clinically significant active infection</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Circulating Tumour Cells</keyword>
	<keyword>HER2 negative primary breast cancer</keyword>
	<keyword>HER2 positive CTC</keyword>
	<keyword>Trastuzumab</keyword>
</DOC>